Research programme: apomorphine prodrugs - Fabre Kramer

Drug Profile

Research programme: apomorphine prodrugs - Fabre Kramer

Alternative Names: FKK 01PD; TGHW 01AP

Latest Information Update: 18 Jan 2017

Price : $50

At a glance

  • Originator Fabre-Kramer Pharmaceuticals
  • Class Antiparkinsonians; Erectile dysfunction therapies
  • Mechanism of Action Dopamine D1 receptor agonists; Dopamine D2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Erectile dysfunction; Parkinson's disease

Most Recent Events

  • 18 Jan 2017 Preclinical development is ongoing for Parkinson's disease and Erectile dysfunction in USA (Fabre Kramer website, January 2017)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Erectile-dysfunction in USA (PO, Capsule)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Parkinson's-disease in USA (PO, Capsule)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top